RLYB News and Press, Rallybio Corporation From 04/11/24

2024-04-11 12:55:33 ET More on Mid-day movers & stocks. Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript Veru Inc. (VERU) Q1 2024 Earnings Call Transcript Veru gets Na...

2024-04-11 10:04:28 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Well...

A look at the top 10 most actives in the United States Verb Technology Company Inc. (VERB) rose 11.3% to $0.2025 on volume of 40,515,259 shares Rallybio Corporation (RLYB) rose 80.4% to $2.9401 on volume of 39,492,767 shares Trio Petroleum Corp. (TPET) rose 36.3% to $0.2499 on volume of 3...

2024-04-11 07:37:24 ET DENVER, Colo., Apr 11, 2024 ( 247marketnews.com )- Rallybio Corporation (NASDAQ: RLYB ) stated that it’s collaborating with Johnson & Johnson to develop complementary therapeutic approaches that reduce the risk of fetal and neonatal alloimmune throm...

2024-04-11 07:00:37 ET Rallybio ( NASDAQ: RLYB ) shares surged in premarket trading on Thursday, on collaboration with Johnson & Johnson ( NYSE: JNJ ) to support the development of complementary therapeutic approaches aimed at reducing the risk of fetal and neon...

2024-04-10 17:20:42 ET Gainers: Rallybio Corporation ( RLYB ) +42% . Alpine Immune Sciences ( ALPN ) +36% . Vera Therapeutics ( VERA ) +10% . Relay Therapeutics ( RLAY ) +7% . Olema Pharmaceuticals  ( OLMA ) +5% . Lose...

- Rallybio to Receive Funding for FNAIT Awareness Initiative and Equity Investment from Johnson & Johnson - Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for ...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that data from a systematic literature review assessing the frequency ...

2024-03-12 09:49:57 ET More on Rallybio Jefferies cuts Rallybio to hold, cites lack of near-term catalysts Rallybio shares jump 13% on restructuring, cash runway extension Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Rallybio ...

-- Received Protocol Assistance Feedback from European Medicines Agency on the Phase 2 Study for RLYB212; Company to Proceed Forward with Clinical Trial Application Process in Europe -- -- Phase 2 Dose Confirmation Study for RLYB212 in Pregnant Women at Higher Risk for FNAIT Expected to I...